Long-term safety from the raltegravir clinical development program.
about
Neurological and psychiatric adverse effects of antiretroviral drugs.96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.Neuropsychiatric Effects of HIV Antiviral Medications.Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individualsIncidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial.Psychiatric Symptoms in Patients Receiving Dolutegravir.Neuronal Stress and Injury Caused by HIV-1, cART and Drug Abuse: Converging Contributions to HAND.Cost-effectiveness of raltegravir in HIV/AIDS.Antiretroviral therapy: effects on orofacial health and health care.Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir.Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals.Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens.A safety evaluation of raltegravir for the treatment of HIV.
P2860
Q34039419-223C8849-07F8-49B2-A45F-9AF8998DA134Q34341541-7686E1DE-AD21-4EAF-970D-A780495C11F2Q34537705-B04D3066-554B-45D9-9D25-6E16E7DADEFBQ35789343-4EC15E61-416F-42EA-ABA7-901EF305ED31Q36018556-E74A9746-D386-4D7A-BEBC-5924815A0254Q36759898-2E34CB97-C1AA-4FD0-9503-796258B54918Q37659135-553E149D-5E92-47E8-A7E8-271FDFA050A3Q37721505-1740AD10-2079-44F1-8D3B-C2CB1155942BQ37958046-D710A9EE-C95E-48BC-BF35-B8133032F917Q38093238-D271F84D-7C66-4C95-B9D5-E333131405B2Q38860427-E0B31C00-B596-42EB-AEF6-869451B9B61EQ38882614-166609CA-5B8F-4AEB-AB75-33564A69096EQ40051820-8A22AC82-E461-4BA0-A69A-8C97F1932526Q41990454-B0FE687E-DDB4-4487-8E47-8242BE246A0FQ47377203-7C64C7EE-1639-4CA2-814F-6E20D945A34F
P2860
Long-term safety from the raltegravir clinical development program.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Long-term safety from the raltegravir clinical development program.
@ast
Long-term safety from the raltegravir clinical development program.
@en
type
label
Long-term safety from the raltegravir clinical development program.
@ast
Long-term safety from the raltegravir clinical development program.
@en
prefLabel
Long-term safety from the raltegravir clinical development program.
@ast
Long-term safety from the raltegravir clinical development program.
@en
P2093
P2860
P1433
P1476
Long-term safety from the raltegravir clinical development program.
@en
P2093
Bach-Yen T Nguyen
Deborah D Brown
Fabio Lievano
Hedy Teppler
Heidi P Lehman
Peter Sklar
Randi Y Leavitt
T Christopher Mast
P2860
P356
10.2174/157016211794582650
P577
2011-01-01T00:00:00Z